ArticleMolecular cancer research : MCR2019
Effects of Oncogenic Gα
Open access · bronzeAbstract read
In one paragraph
Article in Molecular cancer research : MCR, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed
10.2field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 94 citations in OpenAlex.
- Gene therapy for uveal melanoma.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2026Review
- Identification of targetable epigenetic vulnerabilities for uveal melanoma.Cell death & disease · 2025Article
- Allele-specific depletion ofMolecular therapy. Oncology · 2025Article
- The thiazolidinedione drug troglitazone inhibits Gq signaling through direct binding to the Gq alpha subunit through inhibition of GDP release.Molecular pharmacology · 2025Article
- Cyclic peptide inhibitors function as molecular glues to stabilize Gq/11 heterotrimers.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The guanine nucleotide exchange factor Ric-8A regulates the sensitivity of constitutively active Gαq to the inhibitor YM-254890.The Journal of biological chemistry · 2025Article
- The Gq/11 family of Gα subunits is necessary and sufficient for lower jaw development.Development (Cambridge, England) · 2025Article
- QSP modeling of a transiently inactivating antibody-drug conjugate highlights benefit of short antibody half life.Journal of pharmacokinetics and pharmacodynamics · 2024Article
- Neuropeptide Precursor VGF Promotes Liver Metastatic Colonization of Gαq Mutant Uveal Melanoma by Facilitating Tumor Microenvironment via Paracrine Loops.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2024Article
- Going Rogue: Mechanisms, Regulation, and Roles of Mutationally Activated GMolecular pharmacology · 2024Review
- The role of signaling pathways mediated by the GPCRs CysLTR1/2 in melanocyte proliferation and senescence.Science signaling · 2024Review
- Structural response of G protein binding to the cyclodepsipeptide inhibitor FR900359 probed by NMR spectroscopy.Chemical science · 2024Article
- Identification of sulfakinin receptor regulating feeding behavior and hemolymph trehalose homeostasis in the silkworm, Bombyx mori.Scientific reports · 2024Article
- Review
- Recommended Tool Compounds: Application of YM-254890 and FR900359 to Interrogate GαACS pharmacology & translational science · 2023Review
- The Bacterial GJournal of chemical ecology · 2023Article
- Article
- IGF1R Inhibition Enhances the Therapeutic Effects of Gq/11 Inhibition in Metastatic Uveal Melanoma Progression.Molecular cancer therapeutics · 2023Article
- The future of targeted kinase inhibitors in melanoma.Pharmacology & therapeutics · 2022Review
- Protein kinase inhibitor responses in uveal melanoma reflects a diminished dependency on PKC-MAPK signaling.Cancer gene therapy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 4 institutions in 2 countries.
Dominic LapadulaDepartment of Biochemistry and Molecular Biology, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Eduardo FariasDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Clinita E RandolphDepartment of Biochemistry and Molecular Biology, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Timothy J PurwinDepartment of Cancer Biology, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Dougan McGrathDepartment of Biochemistry and Molecular Biology, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Thomas H CharpentierDepartment of Biochemistry and Molecular Biology, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Lihong ZhangCollege of Life Sciences, Zhejiang University, Hangzhou, P.R. China.
Shihua WuCollege of Life Sciences, Zhejiang University, Hangzhou, P.R. China.
Mizue TeraiDepartment of Medical Oncology, Sidney Kimmel Medical College, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Takami SatoDepartment of Medical Oncology, Sidney Kimmel Medical College, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Gregory G TallDepartment of Pharmacology, University of Michigan Medical Center, Ann Arbor, Michigan.
Naiming ZhouCollege of Life Sciences, Zhejiang University, Hangzhou, P.R. China.
Philip B WedegaertnerDepartment of Biochemistry and Molecular Biology, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.ORCID 0000-0001-9264-4759
Andrew E AplinDepartment of Cancer Biology, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania.
Julio Aguirre-GhisoDepartment of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York.
Jeffrey L BenovicDepartment of Biochemistry and Molecular Biology, Cancer Cell Biology and Signaling Program, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania. jeffrey.benovic@jefferson.edu.
Sidney Kimmel Cancer Center · USZhejiang University · CNTisch Hospital · USUniversity of Michigan · US
Funding
X-Ray Crystallography and Macromolecular CharacterizationP30CA056036 · NCI · THOMAS JEFFERSON UNIVERSITY · PI DANIEL P SILVER · 1995 to 2026
$94.8MProject 4 - OGR1- and TSPO- dependent mechanisms mediated by benzodiazepines affecting ASM contractionP01HL114471 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI PANETTIERI, REYNOLD ALEXANDER · 2013 to 2023
$23.9MFunctional Determinants of Metastatic DormancyR01CA109182 · NCI · STATE UNIVERSITY OF NEW YORK AT ALBANY · PI AGUIRRE-GHISO, JULIO A. · 2005 to 2025
$8.3MRegulation of Heterotrimeric G proteins by non-receptor activatorsR01GM088242 · NIGMS · UNIVERSITY OF ROCHESTER · PI TALL, GREGORY GORDON · 2009 to 2022
$4.2MPALMITOYLATION AND TARGETING OF G PROTEINSR01GM056444 · NIGMS · THOMAS JEFFERSON UNIVERSITY · PI WEDEGAERTNER, PHILIP B · 1998 to 2016
$4.2MEpigenetic and microenvironmental regulation of dormant disseminated cancerR01CA218024 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI AGUIRRE-GHISO, JULIO A., BERNSTEIN, EMILY · 2017 to 2021
$2.2MGenome-edited uveal melanoma cell lines for investigating constitutively active GNAQ and GNA11R03CA202316 · NCI · THOMAS JEFFERSON UNIVERSITY · PI WEDEGAERTNER, PHILIP B · 2016 to 2017
$156kTargeting G alpha q/11 in Uveal MelanomaF31CA225064 · NCI · THOMAS JEFFERSON UNIVERSITY · PI LAPADULA, DOMINIC · 2018 to 2020
$135kUnderstanding G alpha q/11 localization and trafficking in uveal melanomaF31CA224803 · NCI · THOMAS JEFFERSON UNIVERSITY · PI RANDOLPH, CLINITA · 2017 to 2020
$135kNCI NIH HHS F31 CA224803NCI NIH HHS F31 CA225064NCI NIH HHS P30 CA056036NCI NIH HHS R01 CA109182NCI NIH HHS R01 CA218024NCI NIH HHS R03 CA202316NHLBI NIH HHS P01 HL114471NIGMS NIH HHS R01 GM056444NIGMS NIH HHS R01 GM088242
Abstract
Uveal melanoma is the most common intraocular tumor in adults and often metastasizes to the liver, leaving patients with few options. Recurrent activating mutations in the G proteins, Gα
Indexed as
AnimalsCell Growth ProcessesCell Line, TumorDepsipeptidesGTP-Binding Protein alpha SubunitsGTP-Binding Protein alpha Subunits, Gq-G11Guanosine 5'-O-(3-Thiotriphosphate)HumansInsectaMAP Kinase Signaling SystemMelanomaRatsRecombinant ProteinsUveal MelanomaUveal NeoplasmsDepsipeptidesFR900359GNA11 protein, humanGTP-Binding Protein alpha SubunitsGTP-Binding Protein alpha Subunits, Gq-G11Guanosine 5'-O-(3-Thiotriphosphate)Recombinant Proteins
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.